There are 702 resources available
53P - Trifluridine/tipiracil plus capecitabine and bevacizumab as upfront treatment for metastatic colorectal cancer: Results of the phase I TriComB study
Presenter: Paolo Ciracì
Session: Poster Display session
54P - Phase I dose-escalation study of trifluridine/tipiracil plus XB2001 and bevacizumab in chemorefractory advanced colorectal cancer: The TASKIN study
Presenter: Nicolas Roussot
Session: Poster Display session
55P - Safety, efficacy, and biomarkers of ONO-4578, an EP4 antagonist, in combination with nivolumab and chemotherapy in treatment-naive and proficient mismatch repair (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Presenter: Yoshinori Kagawa
Session: Poster Display session
56P - Systemic inflammation in liver vs non-liver metastatic microsatellite stable (MSS) colorectal cancer (CRC): An analysis of 2186 patients (pts) from the observational study BMI-QoL and the phase II and III trials MACBETH, MOMA, ATEZOTRIBE, TRIBE, TRIBE2, T
Presenter: Vincenzo Formica
Session: Poster Display session
57P - Evaluating the patient-level association between progression-free survival and overall survival in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer (MSI-H/dMMR mCRC) treated with immune checkpoint inhibitors
Presenter: Jeanine Roodhart, Ashley Tate
Session: Poster Display session
58P - Pooled safety and efficacy analysis of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) for metastatic colorectal cancer (mCRC) using individual patient data (IPD) from five clinical trials
Presenter: Kentaro Yamazaki
Session: Poster Display session
59P - Matching-adjusted indirect treatment comparisons (MAIC) of sotorasib 960mg (soto960) plus panitumumab (pani) vs trifluridine/tipiracil(T/T) plus bevacizumab (bev) in chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Lisa Salvatore
Session: Poster Display session
60P - Comparison of the efficacy of third-line treatments for metastatic colorectal cancer: A network meta-analysis
Presenter: Julien Taieb
Session: Poster Display session
61P - Safety and efficacy of encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: A systematic review and single-arm meta-analysis
Presenter: Davi Said Celso
Session: Poster Display session
62P - Efficacy of neoadjuvant chemotherapy in patients (pts) with locally advanced colon cancer (LACC) in the different subgroups: Results of the meta-analysis
Presenter: Mikhail Fedyanin
Session: Poster Display session